(NASDAQ: LAB) Standard Biotools's forecast annual revenue growth rate of -18.81% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.34%.
Standard Biotools's revenue in 2026 is $128,827,000.On average, 4 Wall Street analysts forecast LAB's revenue for 2026 to be $31,657,040,315, with the lowest LAB revenue forecast at $30,262,990,689, and the highest LAB revenue forecast at $33,191,840,882. On average, 4 Wall Street analysts forecast LAB's revenue for 2027 to be $32,489,239,871, with the lowest LAB revenue forecast at $30,564,489,974, and the highest LAB revenue forecast at $34,540,511,789.
In 2028, LAB is forecast to generate $33,853,293,394 in revenue, with the lowest revenue forecast at $31,845,861,933 and the highest revenue forecast at $36,267,595,064.